Avidity Biosciences (RNA) Price & Analysis

Compare

1,047 Followers

RNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.51 - $56.00

Previous CloseN/A

Volume185.29K

Average Volume (3M)2.89M

Market Cap

$5.82B

Enterprise Value$2.44B

Total Cash (Recent Filing)$1.38B

Total Debt (Recent Filing)$5.97M

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Nov 11, 2025

EPS Estimate

-1.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.21

Shares Outstanding120,538,360

10 Day Avg. Volume4,617,964

30 Day Avg. Volume2,894,126

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.42

Enterprise Value/Revenue273.44

Enterprise Value/Gross Profit296.24

Enterprise Value/Ebitda-5.66

Forecast

1Y Price Target

$67.71

Price Target Upside42.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering18

Bulls Say, Bears Say

Bulls Say

Market LeadershipRNA is viewed as one of the leaders in the muscular dystrophy space with assets in pivotal stages of development, expected to be first-to-market.

Regulatory ProgressRecent regulatory alignment in FSHD is seen as a best-case scenario for the company, providing a clear line of sight to approval.

Takeover BidAvidity Biosciences is trading up intrasession following media reports that Novartis is considering a takeover bid for the company.

Bears Say

Delayed FilingA potential BLA filing is now expected in late 2026, vs. prior 1H26.

Trial Timeline ExtensionChange in DYN's AA primary endpoint from splicing index to vHOT requires a modest increase in trial size, thus extending timeline by a few months.

Avidity Biosciences News

Avidity Biosciences price target raised to $75 from $70 at Wells Fargo

Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an...

4h ago

RNA

Avidity Biosciences price target raised to $62 from $59 at Barclays

Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $62 from $59 and keeps an Overweight...

5h ago

RNA

Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)

Reports Q2 revenue $3.8M, consensus $1.61M. Expects that its cash, cash equivalents and marketable securities as of June...

18h ago

RNA

Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz

The major averages were higher near noon, led by the Nasdaq, as investors reacted to another heavy dose...

2d ago

Avidity up over 20% to $46.05 after FT report of buyout interest

11:44 EDT Avidity up over 20% to $46.05 after FT report of buyout interest Published first on TheFly...

2d ago

RNA

Novo Nordisk made takeover approach to Avidity Biosciences, FT reports

11:16 EDT Novo Nordisk (NVO) made takeover approach to Avidity Biosciences (RNA), FT reports Published first on TheFly...

2d ago

NVO

RNA

Avidity jumps 3% to $39.47 after FT report of takeover approach

11:17 EDT Avidity jumps 3% to $39.47 after FT report of takeover approach Published first on TheFly –...

2d ago

RNA

Avidity Biosciences trading resumes

11:20 EDT Avidity Biosciences (RNA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2d ago

RNA

Novartis makes takeover approach for Avidity Biosciences, FT reports

Novartis (NVS) has made a takeover offer for Avidity Biosciences (RNA), which has a market value of $4.3B,...

2d ago

NVS

RNA

Avidity Biosciences trading halted, volatility trading pause

11:15 EDT Avidity Biosciences (RNA) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

2d ago

RNA

Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks

With the summer of 2025 in full swing, all eyes are once again on President Trump’s trade moves....

27d ago

RNA

ACHV

Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating

Needham analyst Joseph Stringer has maintained their bullish stance on RNA stock, giving a Buy rating today. Joseph...

4h ago

RNA

Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position

Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on Avidity Biosciences, boosting the price target to...

5h ago

RNA

Avidity Biosciences Signs Manufacturing Agreement with Lonza

Avidity Biosciences ( ($RNA) ) has shared an announcement. On August 1, 2025, Avidity Biosciences entered into a...

17h ago

RNA

RNA FAQ

What was Avidity Biosciences Inc’s price range in the past 12 months?

Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $56.00 in the past 12 months.

What is Avidity Biosciences Inc’s market cap?

Avidity Biosciences Inc’s market cap is $5.82B.

When is Avidity Biosciences Inc’s upcoming earnings report date?

Avidity Biosciences Inc’s upcoming earnings report date is Nov 11, 2025 which is in 95 days.

How were Avidity Biosciences Inc’s earnings last quarter?

Avidity Biosciences Inc released its earnings results on Aug 07, 2025. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$0.958 by -$0.252.

Is Avidity Biosciences Inc overvalued?

According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avidity Biosciences Inc pay dividends?

Avidity Biosciences Inc does not currently pay dividends.

What is Avidity Biosciences Inc’s EPS estimate?

Avidity Biosciences Inc’s EPS estimate is -1.1.

How many shares outstanding does Avidity Biosciences Inc have?

Avidity Biosciences Inc has 120,538,360 shares outstanding.

What happened to Avidity Biosciences Inc’s price movement after its last earnings report?

Avidity Biosciences Inc reported an EPS of -$1.21 in its last earnings report, missing expectations of -$0.958. Following the earnings report the stock price went down -1.533%.

Which hedge fund is a major shareholder of Avidity Biosciences Inc?

Currently, no hedge funds are holding shares in RNA

Avidity Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.19%

Trailing 12-Months

Asset Growth

53.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$67.71

▲(42.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,40.541538461538465,45.16307692307693,49.784615384615385,54.40615384615385,59.02769230769231,63.64923076923077,68.27076923076923,72.8923076923077,77.51384615384616,82.13538461538462,86.75692307692307,91.37846153846155,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,38.36538461538461,40.81076923076923,43.25615384615384,45.70153846153846,48.14692307692307,50.592307692307685,53.0376923076923,55.48307692307692,57.928461538461534,60.373846153846145,62.819230769230764,65.26461538461538,{"y":67.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,37.003076923076925,38.08615384615385,39.16923076923077,40.252307692307696,41.33538461538462,42.41846153846154,43.50153846153846,44.58461538461539,45.667692307692306,46.75076923076924,47.83384615384615,48.91692307692308,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >